TransCon PTH (palopegteriparatide, approved under the brand name YORVIPATH in the European Union and certain other countries as a replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism) is a prodrug of PTH (1-34), administered subcutaneously once daily, with sustained release of active PTH designed to provide PTH levels within the physiological range for 24 hours/day for adults with hypoparathyroidism. This evidence concerns the gene PTH and hypoparathyroidism.